Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
Roche Holding AG Bearer Shares RO
News
Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug
Roche CEO Signals New Wave of Drugs to Fuel Growth Next Year, Beyond — Update
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion — Update
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
Roche Gets FDA Approval for Enspryng to Treat Thyroid Eye Disease
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
Roche Licenses Obesity Therapy From China's Rona in Up to $1.2 Billion Deal
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer
Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC
Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
United States